Won Ki Kang
YOU?
Author Swipe
View article: Comprehensive analysis of <i>KRAS</i> aberrations in pan-cancer, with a focus on prognostic and therapeutic implications
Comprehensive analysis of <i>KRAS</i> aberrations in pan-cancer, with a focus on prognostic and therapeutic implications Open
Background: KRAS is one of the most frequently mutated oncogenes in humans. KRAS aberrations play a significant role in various solid tumors, affecting patient prognosis and treatment outcomes. Objectives: We identified features of genetic…
View article: Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4) Open
These findings demonstrate the clinical benefit of nivolumab combined with chemotherapy (either SOX or CAPOX) for first-line treatment of gastric cancer/gastroesophageal junction cancer in Korean patients.
View article: Knowledge Gaps and Emergency Management Practices of Children’s Dental Trauma: A Cross-Sectional Survey Among Primary School Health Teachers and Parents in Urumqi
Knowledge Gaps and Emergency Management Practices of Children’s Dental Trauma: A Cross-Sectional Survey Among Primary School Health Teachers and Parents in Urumqi Open
BackgroundThis study assesses knowledge gaps and influencing factors among primary school health teachers and parents in Urumqi, aiming to bridge disparities in dental trauma management. By identifying critical gaps—such as misconceptions …
View article: The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer
The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer Open
Immune checkpoint inhibitors (ICIs) are used as salvage treatments for advanced gastric cancer (AGC) regardless of HER2 status. This study assessed the efficacy of ICIs based on HER2 expression in AGC patients who received pembrolizumab as…
View article: Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1
Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1 Open
BACKGROUND Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, inhibits angiogenesis and reduces tumor growth. Serum VEGF-C, lactate dehydrogenase, and inflammatory markers have been reported as predictive m…
View article: Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement
Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement Open
Purpose: For the treatment of locally advanced rectal cancer (LARC), research on primary lesions with mesorectal fascia (MRF) involvement is lacking. This study analyzed the clinical outcomes and efficacy of dose-escalated neoadjuvant conc…
View article: Table S5 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S5 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Significant covarying programs
View article: Figure S11 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S11 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S11. Mean usage of myeloid cNMF programs per myeloid cell subset at (A) baseline, (B) post-chemotherapy (FU1) and (C) post-immunotherapy (FU2). Mean usage of T cell cNMF programs per T cell cell subset at (D) baseline, (E) postchemo…
View article: Figure S8 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S8 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S8. Copy number profiles of all epithelial cells from each patient’s samples inferred using inferCNV.
View article: Table S8 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S8 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Representativeness of study participants
View article: Table S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Annotated cNMF programs
View article: Figure S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S2. (A) CoMut plot demonstrating TCGA subtype, tumor mutational burden, mutational signature enrichment and mutational profiles of key driver genes for all patient samples at baseline in the reported clinical trial. (B) PD-L1 expres…
View article: Figure S14 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S14 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S14. cNMF was performed on epithelial cells at baseline. Shown is the mean usage of each cNMF gene program in the epithelial cells of fast and slow progressing patients.
View article: Figure S23 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S23 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S23. Heatmaps showing the number of significant inferred ligandreceptor interactions between major cell types using CellPhoneDB on scRNAseq data in (A) normal, (B) baseline tumor, (C) post-chemotherapy (FU1) tumor and (D) post-immun…
View article: Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
(A) Swimmers plot of patient response and duration in the described clinical trial. (B) Scatter plot showing temporal course of tumor response measured by RECIST for all patients in the reported clinical trial. (C) Progression free surviva…
View article: Figure S23 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S23 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S23. Heatmaps showing the number of significant inferred ligandreceptor interactions between major cell types using CellPhoneDB on scRNAseq data in (A) normal, (B) baseline tumor, (C) post-chemotherapy (FU1) tumor and (D) post-immun…
View article: Figure S24 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S24 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S24. (A) Immune gene expression program signature scored from bulk RNA-seq profiles across all samples separated by timepoint. (B) Immunogenic cell death signatures scored from bulk RNA-seq profiles split by fast and slow progressin…
View article: Figure S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S4. Multiplexed immunofluorescence (mIF) images of BL and FU1 samples from two patients, E17 (slow progressor) and E35 (fast progressor), staining for (A) panCK, PD-L1, CD163, CD68, CD14 and CD8, and (B) panCK, PD-L1, CD4, CD8 and G…
View article: Figure S13 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S13 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S13. Boxplots showing usage of epithelial cNMF programs in epithelial cells of fast and slow progressors (A) post-chemotherapy (FU1) and (B) postimmunotherapy (FU2).
View article: Table S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Adverse events on single arm sequential CAPOX and pembrolizumab in advanced gastric cancer.
View article: Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
(A) Swimmers plot of patient response and duration in the described clinical trial. (B) Scatter plot showing temporal course of tumor response measured by RECIST for all patients in the reported clinical trial. (C) Progression free surviva…
View article: Table S7 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S7 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
CellPhoneDB unique ligand receptor interactions
View article: Figure S26 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S26 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S26. (A) Proportion of CD8 T cells in non-responder and responder patients split by timepoint. Statistical comparisons performed using a Wilcoxon signed-rank test. (B) Multiplexed immunofluorescence (mIF) images of BL, FU1 and FU2 s…
View article: Data from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Data from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Adding anti–programmed cell death protein 1 (anti–PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted …
View article: Table S5 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S5 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Significant covarying programs
View article: Table S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S2 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Adverse events on single arm sequential CAPOX and pembrolizumab in advanced gastric cancer.
View article: Figure S19 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Figure S19 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Figure S19. (A) UMAP embedding of single cell transcriptomes of all macrophages obtained from all samples in this trial. Labeled are granular macrophage subsets separated by tumor v.s. normal tissue, and by timepoint. (B) UMAP embeddings s…
View article: Table S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Table S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Open
Patient demographics